Avai Bio (AVAI) Cash from Financing Activities (2018 - 2026)

Avai Bio (AVAI) has 9 years of Cash from Financing Activities data on file, last reported at $23570.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 91.12% year-over-year to $23570.0; the trailing twelve-month figure through Mar 2026 stood at $951936.0 (down 23.32% YoY), and the FY2026 full-year result was $951936.0, down 23.32% from the prior year.
• Cash from Financing Activities declined to $23570.0 in Q1 2026, from $305534.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.0 million in Q1 2022 to a low of -$55248.0 in Q3 2022.
• A 5-year average of $278485.7 and a median of $162153.0 in 2023 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 6644.1% in 2022, while the deepest fall reached 127.86% in 2022.
• Tracing AVAI's Cash from Financing Activities over 5 years: stood at -$17665.0 in 2022, then surged by 4091.42% to $705085.0 in 2023, then sank by 80.76% to $135651.0 in 2024, then soared by 125.24% to $305534.0 in 2025, then plunged by 92.29% to $23570.0 in 2026.
• Business Quant data shows AVAI's Cash from Financing Activities at $23570.0 in Q1 2026, $305534.0 in Q4 2025, and $453480.0 in Q3 2025.